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Abstract
Background: The non-invasive diagnosis of cardiac sarcoidosis (CS) is difficult. Cardiovascular magnetic resonance (CMR)
has become a very valuable diagnostic tool in patients with suspected CS, but usually a combination of different tests is
used. Oxygen uptake efficiency slope (OUES) is a parameter of cardiopulmonary exercise testing (CPET), which is used as an
indicator for cardiovascular impairment. We investigated the predictive value of OUES for the diagnosis of myocardial
involvement in sarcoid patients.
Methods: Retrospectively 37 consecutive patients (44.9613.8 years) with histologically confirmed sarcoidosis and clinical
suspicion of heart involvement underwent noninvasive diagnostic testing including CMR. CS was diagnosed according to
the guidelines from the Japanese Society of Sarcoidosis and other Granulomatous Disorders with additional consideration
of CMR findings. Furthermore, CPET with calculation of predicted OUES according to equations by Hollenberg et al. was
carried out.
Results: Patients with CS (11/37; 30%) had a worse cardiovascular response to exercise. OUES was significantly lower in CS-
group compared to non-CS-group (59.3619.1 vs 88.0615.4%pred., p,0.0001). ROC curve method identified 70%pred. as
the OUES cut-off point, which maximized sensitivity and specificity for detection of CS (96% sensitivity, 82% specificity, 89%
overall accuracy). OUES ,70%pred. was the single best predictor of CS (Odds ratio: 100.43, 95% CI: 1.99 to 5064, p,0.001)
even in multivariate analyses.
Conclusion: OUES assessed in CPET may be helpful in identifying patient with cardiac involvement of sarcoidosis. Patient
selection for CMR may be assisted by CPET findings in patients with sarcoidosis.
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Introduction
Sarcoidosis is a multisystemic disease of unknown origin in
usually young patients. Lung (90%), liver (30–40%), skin (20–
35%), eyes (20–30%), musculoskeletal (2–38%) and nervous
system (1–5%) are the organs most commonly affected. Cardiac
involvement is associated with a poor prognosis and is extremely
difficult to detect. Although cardiac involvement is present in 5–
30% of patients with systemic sarcoidosis, only about 5% of these
patients are symptomatic [1]. The absence of clinical symptoms
does not rule out cardiac sarcoidosis, which is documented by the
high rate of unexpected cardiac sarcoidosis in postmortem studies
[2,3]. The clinical presentation of sarcoid heart disease includes
congestive heart failure, arrhythmias, conduction disturbances,
pericardial effusion and also sudden death [4]. The diagnosis can
be made by several diagnostic approaches [5] but is confirmed by
either noncaseating granulomas in myocardial biopsy or diagnosed
by evidence of granulomas in any extracardiac tissue in association
with cardiac abnormalities unexplained by other causes. Cardiac
sarcoidosis is much more common in the Japanese population
compared to other regions and is e.g. the leading cause of death
from sarcoidosis in Japan. Therefore, the Japanese Ministry of
Health and Welfare published in 1993 guidelines for diagnosing
cardiac sarcoidosis [6], which were revised in 2006 by the
Japanese Society of Sarcoidosis and other Granulomatous
Disorders (Table 1) [7]. These guidelines combine the results of
various diagnostic tests and provide an useful framework,
particularly for patients with proven systemic sarcoidosis in whom
cardiac involvement is suspected. However, cardiovascular mag-
netic resonance imaging (CMR) has become a diagnostic tool of
growing impact for noninvasive assessment of myocardial inflam-
mation in patients with suspected cardiac sarcoidosis[8–11]. Thus,
CMR was included in the revised Japanese guidelines, but is
currently an expensive method with usually limited access.
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Cardiopulmonary exercise testing (CPET) is a widely accessible
method for measuring physical performance including cardiovas-
cular function. The oxygen uptake efficiency slope (OUES) is a
novel parameter derived from oxygen uptake (VO2) and minute
ventilation (VE)[12]. OUES measures cardiopulmonary functional
reserve and may serve for screening of cardiovascular dysfunc-
tion[13]. To our knowledge, this tool has never been applied to
patients with sarcoidosis in order to assess cardiac function. The
aim of this investigation was to find out whether the OUES is a
clinically useful predictor of cardiac involvement in patients with
biopsy specimen-proven sarcoidosis.
Methods
The patient records was anonymized and de-identified prior to
analysis. The study was approved by the ethics committee of the
Charite´-University Medicine Berlin, Germany. We studied retro-
spectively 37 consecutive patients (44.9613.8 years) with biopsy
proven sarcoidosis and clinical evidence for cardiac involvement.
Studies on the issue of cardiac involvement included electrocar-
diography (ECG), transthoracic echocardiography and Holter-
ECG. Further investigation in suspected cardiac sarcoidosis was
cardiovascular magnetic resonance (CMR), in case of unclear
findings a coronary angiography was performed. In brief, cardiac
sarcoidosis was diagnosed according to revised guidelines from the
Japanese Society of Sarcoidosis and other Granulomatous
Disorders (Table1) [7] and additional consideration of clearly
defined CMR-criteria in 11 patients [14]. The study was approved
by the ethics committee of the Charite´-University Medicine Berlin,
Germany.
CMR Studies were performed using a 1.5-T MRI-Scanner
(Achieva, Philips Medical Systems, Amsterdam’, The Netherlands)
with a cardiac-dedicated, five element phased array coil (SENSE),
respectively with a body coil at sequences for semiquantitative
analysis of myocardial inflammation following the recommenda-
tions as described by an International Consensus Group on CMR
Diagnosis of Myocarditis [14]. We examined cardiac function (i.e.,
left ventricular ejection fraction = LVEF, wall motion) with a
steady state free precession gradient echo cine sequence (three long
axis images and at least three short axis images).
T2-weighted triple-inversion-recovery (STIR) images were
acquired during the patient’s breath hold by using the body coil
in short axis. The following parameters were used: 15-mm section
thickness, TE-time of 61-msec. Evidence for regional edema, or a
signal intensity ratio of$2.0 (signal intensity normalized to skeletal
muscle in the same slice), renders T2 findings positive.
EGE was performed before and after the intravenous injection
of 0.2 ml of Gadoteridol (ProHanceH, Bracco IMAGING
Deutschland GmbH, Konstanz, Germany) per kilogram of body
weight for acquisition of transverse sections. The following
parameters were used: repetition time of one R-R interval, TE-
time of 14-msec, 15-mm section thickness. An additional T1-
weighted fast spin-echo saturation section was positioned across
the atria to reduce the blood-signal. Quantitative evaluation of the
signal enhancement (skeletal-muscle normalized myocardial en-
hancement ratio of $4.0 or an absolute enhancement of $45%)
has been considered as a positive criterion.
LGE images were acquired, on average, 10 minutes after the
intravenous administration of a second bolus of Gadoteridol
(0.2 ml/kg) by using a look-locker-sequence to clarify the TI-time
then recovery of two-dimensional inversion-recovery gradient-
echo sequence and a PSIR-sequence on a complete set of short-
axis sections (encompassing the entire LV) and three long-axis
sections (four-, three- and two-chamber views). LE images were
acquired by using 8-mm section thickness. Presence of at least 1
focal lesion with nonischemic regional distribution in inversion
recovery-prepared gadolinium-enhanced T1-weighted images was
considered a positive criterion.
Table 1. Summary of the 2006 revised guidelines of diagnosing cardiac sarcoidosis of the Japanese Society of Sarcoidosis and
Other Granulomatous [7].
I. Histologic diagnosis group:
Endomyocardial biopsy demonstrates noncaseating epithelioid granulomata.
II. Clinical diagnosis group:
Cardiac sarcoidosis is diagnosed in the absence of an endomyocardial biopsy specimen when extracardiac sarcoidosis has been proven and a combination of major or
minor diagnostic criteria has been satisfied as follows:
- More than 2 of 4 major criteria are satisfied, OR
- 1 of the 4 major criteria and 2 or more of the minor criteria are satisfied
Major criteria
(1) Advanced AV block
(2) Basal thinning of the ventricular septum
(3) Positive cardiac gallium uptake
(4) Left ventricular ejection fraction less than 50%
Minor criteria
(1) Abnormal electrocardiogram findings including ventricular tachycardia (VT), multifocal frequent premature ventricular contractions (PVC), complete right bundle
branch block (RBBB), pathologic Q waves or abnormal axis deviation
(2) Abnormal regional wall motion, ventricular aneurysm or unexplained increase in wall thickness
(3) Perfusion defects detected by myocardial scintigraphy
(4) Delayed gadolinium enhancement of the myocardium (LGE) on CMR
(5) Interstitial fibrosis or monocyte infiltration greater than moderate grade by endomyocardial biopsy
RBBB = complete right bundle branch block. VT = ventricular tachycardia. PVC = premature ventricular contraction.
doi:10.1371/journal.pone.0102333.t001
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Data were analyzed using software for evaluating CMR images
(cmr42, Circle Cardiovascular Imaging Inc., Calgary, Canada).
All patients received a complete pulmonary function test (PFT)
according to international recommendations [15–17]. The mea-
surements were obtained by using a MasterScreenH Body/
Diffusion (CareFusion, Hoechberg, Germany). All collected
PFT-parameters were expressed as a percentage of the predicted
values, which were obtained from regression equations by Quanjer
et al [18] and Cotes et al [19].
CPET was carried out on an electromagnetically braked cycle
ergometer (Excalibur Sport, Lode B.V. Groningen, The Nether-
lands) with respiratory gas exchange analysis on a breath-by-
breath basis (MasterScreenH CPX, CareFusion, Hoechberg,
Germany) and additional blood gas analysis according to a
standardized procedure [20]. The used reference values for peak
VO2/kg (ml/min/kg) are based on the recommendations of
Cooper et al. (women: VO2 max/kg = 42.83– (0.371 * years);
men: VO2 max/kg = 50.02– (0.394 * years)) [21].
OUES was computed by a linear least squares regression from
the oxygen uptake (VO2) on the logarithm of the minute
ventilation (VE) according to the following equation: VO2 = a
* log10VE + b. Constant ‘a’ is called the OUES, as it represents the
rate of absolute increase in oxygen uptake in response to a change
in minute ventilation. To compare the OUES results from our
study group with reference values, we estimated the predicted
OUES for age, body surface area (BSA) and sex-matched normal
participants according to the equations published by Hollenberg et
al. (for women: OUES =1175–15.8 * age +841 * BSA; for men:
OUES =1320–26.7 * age +1394 * BSA) [22].
Data were analyzed using IBMH SPSSH Statistics 19 for
WindowsH computer software. All values were reported as mean
6 standard deviation except when specified otherwise. Unpaired
Student’s t-test and Wilcoxon signed-rang-test were used for
appropriate comparisons. Relationships between variables were
assessed by the Pearson’s correlation coefficient (r). The receiver
operating characteristic (ROC) curve method was used to plot the
true positive rate (sensitivity) in function of the false positive rate
(1-specificity) for different cut-off points of predicted OUES values.
To test the simultaneous influence of other independent
predictor variables on the dependent target variable (cardiac
sarcoidosis) and to reduce the risk of overfitting the data we used a
binary logistic regression model with stepwise forward selection
(pin,0.05; pout.0.1). The following candidate variables were
used: radiographic stage (Typ 0 through Typ IV), FEV1 (absolute
value in L), DLCO/VA (%pred), LVEF (%),VO2max (absolute
value in ml/min/kg), OUES (absolute value in ml/min/log(ml/
min)). This analysis was repeated with the cut-off value identified
in the ROC-analyses in order to yield maximal clinical applica-
bility. Results of the multivariable analysis are reported as b-
coefficient, 95% confidence intervals and p-value. A p-value of less
than 0.05 was reported as significant for all analyses.
Results
A total of 37 patients (mean age 44.9613.8 years; 11 female)
was assessed. Demographic, clinical and diagnostic findings for the
groups with cardiac sarcoidosis (11/37, 30%) and without cardiac
sarcoidosis are shown in Tables 2 and 3. Age, gender, height,
weight, Body Surface Area and Body Mass Index did not differ
significantly between the two groups. Only the radiographic
distribution of pulmonary stages was unevenly distributed with
more advanced stages among patients with cardiac involvement
(p=0.031).
Only 1/37 patients (3%) could not be examined by CMR
during the study because he presented a symptomatic 2nd degree
AV block (Mobitz II), and a pacemaker had to be implanted.
However, in this case a transthoracic echocardiography was
performed and showed regional wall motion abnormalities with
normal LV-function and exclusion of pericardial effusion, so that
the patient was not excluded from the study. Of the other 36
patients, 4/36 (11%) had pericardial effusion, 9/36 (25%) patients
had increased global myocardial early gadolinium enhancement
(EGE) ratio in T1-weighted images, 8/36 (22%) patients had
regional or global myocardial SI increase in T2-weighted images
and 6/36 (17%) had local myocyte injury and/or scar, confirmed
by myocardial late gadolinium enhancement (LGE) with typical
nonischemic regional distribution [23].
In 5 patients (14%) cardiac involvement was diagnosed
according to revised guidelines of diagnosing cardiac sarcoidosis
from the Japanese Society of Sarcoidosis and Other Granuloma-
tous Disorders including CMR-findings (Tab. 1) [7]. The
remaining 6 patients (17%) of the cardiac sarcoidosis group
presented at least two of the three tissue-based CMR-findings for
myocardial inflammation and fulfilled the proposed diagnostic
CMR criteria (i.e., Lake Louise Consensus Criteria) for myocar-
ditis [14]. It is likely that abnormalities on CMR in these patients
represent cardiac sarcoidosis even in the absence of clinical cardiac
abnormalities[24].
Cardiac function (LVEF) was mildly impaired on average, but
significantly poorer in the patient group with cardiac sarcoidosis
compared to the group without cardiac sarcoidosis due to the
sarcoidosis associated heart failure after exclusion of other possible
causes (5767 vs 6865%, p,0.0001). Nevertheless, both groups
were in the range of preserved ejection fraction.
No significant differences in the preserved lung function
parameters between the two groups (CS-group vs non-CS-group)
were observed (Tab. 2). 10/37 (27%) patients presented a
ventilatory dysfunction as defined by ATS/ETS guidelines [17]
(4/11, 36% in CS-group vs 6/26, 23% in non-CS-group,
p=0.544). 22/37 (59%) patients showed a decreased transfer
factor (i.e., DLCO corrected for Hb ,80% of predicted; 8/11,
73% in CS-group vs 14/26, 54% in non-CS-group, p=0.384).
All patients completed the cardiopulmonary exercise test
(CPET) without any complication. Mean peak respiratory
exchange ratio (RER) was 1.1460.11. Only two patients stopped
the exercise test before reaching the metabolic exertion (i.e., peak
RER ,1.0) due to pulmonary limitations (1/11, 9% in CS-group
vs 1/26, 4% in non-CS-group, p=0.806).
Mean peak VO2 values were 22.165.8 and 68.5619.3 when
expressed respectively in ml/min/kg and as percent of predicted
value. In comparison to the patient group without cardiac
sarcoidosis the patients with cardiac involvement had lower peak
VO2-values (18.365.9 vs 23.765.1 ml/min/kg, p=0.014) and
significantly lower percentage of predicted peak VO2-values
(55.9621.2 vs 73.9616.0%pred., p=0.005) (Figure 1 upper left
and right panel).
Mean maximal AaDO2 was 36.2611.3 mmHg and showed no
significant difference between both groups (38.9612.5 vs
35.1610.8 mmHg, p=0.358).
In the entire study population, OUES could be calculated and
ranged from 855.79 to 4756.39 [ml/min/log(ml/min)] (mean 6
SD: 2177.566824.15). Absolute OUES values and percentage
of predicted OUES values according to the equations released
by Hollenberg et al. were significantly poorer in the patient group
with evidence of cardiac sarcoidosis (1669.706635.82 vs
2392.436809.25 [ml/min/log(ml/min)], p=0.013 and 59.3619.1
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vs 88.0615.4%pred., p,0.0001, respectively) (Figure 1, lower left and
right panel).
When related to the resting cardiac function, LVEF showed a
positive correlation with predicted peak VO2 values (r=0.414,
p=0.012). Moreover, LVEF was significantly and directly related
to predicted OUES values (r=0.443, p=0.007).
In order to assess and compare operative characteristics of
OUES for the distinctions between patients with and without
cardiac sarcoidosis, ROC-curves were plotted. The area under
curve (AUC) was 0.879 (95% CI: 0.73 to 1.03, p,0.0001)
(Figure 2). 70% of predicted OUES as cut-off point had the largest
diagnostic discriminatory power for diagnosing cardiac sarcoidosis
(96% sensitivity, 82% specificity and 89% overall accuracy)
(Table 4).
Multivariable Analyses
When all candidate variables were included in the regression
model only OUES and LVEF were significantly associated with
the presence of cardiac sarcoidosis (Table 5). When the cut off
point (70% of predicted) for OUES was used in the model, it
returned as the strongest predictor of cardiac sarcoidosis (Odds
ratio: 100.43, 95% CI: 1.99 to 5064, p,0.001). LVEF remained
as a clinical predictor (Odds ratio: 0.776, 95% CI: 0.578 to 1.042,
p=0.092) in both models, but contributed little improvement
(correct classified with OUES (70%pred) 91.7%, adding LVEF
94.4%).
Radiographic findings (i.e., pulmonary stage of sarcoidosis
according to chest x-ray) did not fulfill inclusion criteria of this
method. In addition, neither PFT-parameters associated with
ventilatory impairment nor PFT-parameters associated with gas
exchange disorder qualified for the regression model with cardiac
sarcoidosis as the dependent variable (pin ,0.05).
Discussion
The main findings of the present study were: (1) cardiac
sarcoidosis is associated with a poor cardiovascular response to
exercise and can be verified by CPET. (2) Patients with cardiac
sarcoidosis had significantly lower levels of OUES due to the
sarcoidosis associated heart failure. (3) A cut-off point of OUES
(70% of predicted according to equations published by Hollenberg
et al) was able to discriminate between patients with and without
Table 2. Summary of Demographic, CMR-, Pulmonary function tests and CPET-Data (n = 37).
Group with Cardiac Sarcoidosis Group without Cardiac Sarcoidosis p-value
(n = 11) (n = 26)
Mean age [yrs] 44.3614.6 45.1613.7 NS
Pulmonary stage (0/I/II/III/IV) (0/1/4/3/3) (1/5/18/1/1) 0.031`
height [cm] 177.5612.6 175.7610.8 NS
weight [kg] 82.4615.4 84.7615.2 NS
BMI [kg/m2] 26.063.2 27.564.8 NS
BSA [m2] 1.9960.24 2.0060.21 NS
CMR-findings (n=10) (n =26)
Myocardial EGE (SI) 4.4 (3.0–22.2) 2.9 (1.2–6.6) 0.006`
T2 signal intensity (SI) 2.0 (1.6–2.7) 1.7 (1.2–2.0) 0.0131
LGE (n) 6/10 (60%) 0/26 (0%) ,0.0001`
Abnormal wall motion (n) 6/10 (60%) 2/26 (7.7%) ,0.0001`
Mean LVEF [%] 5669 6766 ,0.00011
Pericardial effusion (n) 2/10 (20%) 2/26 (7.7%) NS
Pulmonary function tests (n=11) (n =26)
FEV1 (%pred) 78.7616.4 86.9619.8 NS
VC (%pred) 77.1621.9 89.7613.5 NS
TLC (%pred) 88.4618.8 100.8614.8 NS
DLCO (%pred) 61.1623.6 78.0618.0 NS
CPET (n = 11) (n = 26)
Peak VO2 abs. [ml/min/kg] 18.365.9 23.765.1 0.0141
Peak VO2 (%pred)* 55.9621.2 73.9616.0 ,0.0051
RER max. 1.1960.14 1.1260.08 NS
AaDO2 max. [mmHg] 38.9612.5 35.1610.8 NS
OUES abs. [l/min/log(l/min)] 1669.706635.82 2392.436809.25 0.0131
OUES (%pred){ 59.3619.1 88.0615.4 ,0.00011
BMI = body mass index; BSA = body surface area; CMR = cardiovascular magnetic resonance; LVEF = left ventricular ejection fraction; CPET = cardiopulmonary
exercise testing; EGE = Early gadolinium enhancement; LGE = Late gadolinium enhancement.
*Reference values according to equations published by Cooper et al. [21]
{Reference values according to equations published by Hollenberg et al [22].
`Wilcoxon signed-rang-test.
1Unpaired Student’s t-test.
doi:10.1371/journal.pone.0102333.t002
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cardiac sarcoidosis (Odds ratio: 100.43, 95% CI: 1.99 to 5064, p,
0.001).
In order to identify and treat patients with cardiac involvement
in histologically proven sarcoidosis at an early stage a screening-
series of noninvasive diagnostic approaches is recommended.
However, the incidence of cardiac involvement is much higher
when specific cardiac tests are performed in unselected patients
with sarcoidosis [25–27]. This finding underscores the fact, that
patients with cardiac sarcoidosis are often asymptomatic and a
potentially dangerous cardiac involvement may remain undetect-
ed. Several studies showed that cardiovascular magnetic resonance
(CMR) imaging improves the sensitivity and specificity of diagnosis
of cardiac sarcoidosis [14,28–30]. Late gadolinium enhancement
has emerged as the dominant CMR sequence for evaluation of
cardiac sarcoidosis [28–30]. Preliminary observations suggest that
monitoring gadolinium enhancement may also be helpful in the
assessment of the efficacy of steroid therapy [11]. Patel et al.
compared late gadolinium enhancement CMR with Japanese
Ministry of Health and Welfare (JMH) criteria in a series of 81
patients with biopsy proven extracardiac sarcoidosis [30]. In this
study late gadolinium enhancement was more than twice as
sensitive for CS as JMH criteria.
In order to assess best diagnostic accuracy of CS, revised
Japanese guidelines including late gadolinium enhancement CMR
and the CMR criteria according to the International Consensus
Group on CMR Diagnosis of Myocarditis were applied in our
study [7,14].
The present study investigated the usefulness of CPET with
calculation of OUES for the evaluation of patients with sarcoidosis
in a setting that could become part of a routine screening.
In line with previous studies, we found that cardiac function
(i.e., LVEF) was closely related to OUES [31,32]. Interestingly, we
also demonstrated that in patients with sarcoidosis cardiac
involvement was associated with a poor cardiovascular exercise
performance, both in terms of oxygen uptake (peak VO2) and
oxygen uptake efficiency slope (OUES). Peak VO2 is strongly
influenced by the motivation of the patient, the selected exercise
protocol and the tester’s subjective choice of the test end point
[33]. In contrast, the OUES is an objective and reproducible
measure of cardiopulmonary function reserve that can also be
measured with submaximal exercise [34]. Therefore, OUES is a
better parameter of CPET in order to evaluate patients with
sarcoidosis and should be calculated and recorded with peak VO2.
In the present study, we found that evidence for sarcoid heart
failure was associated with decreased levels of oxygen uptake
efficiency during exercise. The chance to diagnose cardiac
sarcoidosis in patients with an OUES ,70% of predicted was
67-times higher than in patients with an OUES .70% of
predicted. In addition, only OUES remained in the multiple
regression model with cardiac sarcoidosis as the dependent
variable, when possible confounders were offered in the statistical
Figure 1. Comparison of CPET parameters in patients with and without cardiac sarcoidosis (CS). Peak VO2 [ml/min/kg] upper left, peak
VO2 [% of predicted] upper right, OUES [ml/min/log(ml/min)] lower left, and OUES (% of predicted) lower right panel. All panels: Outliers (values that
are between 1.5 and 3 times the interquartile range) are represented by circles beyond the whiskers. Extreme values (values that are more than 3
times the interquartile range) are represented by asterisk beyond the whiskers. P-values are given for the univariable comparison.
doi:10.1371/journal.pone.0102333.g001
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Figure 2. The Receiver Operating Characteristic (ROC) curve of different OUES cut-off points (%pred) and CS diagnosis. A OUES ,
70% of predicted as cut-off point had the largest diagnostic discriminatory power for diagnosing cardiac sarcoidosis.
doi:10.1371/journal.pone.0102333.g002
Table 4. Association between observed and predicted cardiac sarcoidosis according to the best OUES cut-off point at 70% of
predicted.
Predicted
No Cardiac sarcoidosis Cardiac sarcoidosis Total Percentage
(n = OUES .70%pred) (n = OUES ,70%pred) (n) correct (%)
Observed
No cardiac sarcoidosis (n) 25 (true negative) 1 (false positive) 26 96.2
Cardiac sarcoidosis (n) 3 (false negative) 8 (true positive) 11 72.7
Overall correct (%) 89.2
doi:10.1371/journal.pone.0102333.t004
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model. Therefore these findings strongly suggest that a reduced
cardiovascular performance measured by OUES is associated with
cardiac sarcoidosis.
In the interpretation of our study results, some possible
limitations have to be discussed. First, the number of included
patients was limited and our results should be prospectively
confirmed in a larger cohort, before CPET and OUES is
introduced into the assessment routine of patients with sarcoidosis.
However, the predictive power of OUES for results of CMR was
strong (OR 67) and plausible which makes controversial future
findings unlikely. Secondly, we cannot rule out that the degree of
physical fitness and the extent of pulmonary impairment may also
affect the relationship between oxygen uptake and ventilation
during exercise in individual patients with sarcoidosis [35]. For
example, the false positive tested patient in our study showed a
moderate restrictive ventilatory impairment and a significant gas
exchange disorder in rest and during exercise. Third, we did not
analyze complete medication history and future longitudinal
studies are needed to determine whether a therapy with
corticosteroids or other immunosuppressants is also associated
with an increase of OUES in patients with cardiac sarcoidosis. The
effect of drug intervention could be a plausible reason for the false
negative findings in our study. But we felt that the diagnosis of
cardiac sarcoidosis was only firmly established when patients with
less than three CMR-criteria also fulfilled the Japanese Society
Criteria. The may have biased the results towards sicker patients.
However, we wanted to focus on patients with possible clinical
consequences, such as high dose corticosteroid treatment. On one
hand, we could therefore include the patient who had already
cared for with a cardiac pacemaker and thus clinically cardiac
sarcoidosis. On the other hand, the absence of significant
functional cardiac disorders could explain the elevated OUES
values in the false negative tested patients. It is well known that the
clinical manifestations of cardiac sarcoidosis depend upon the
location and the extent of the myocardium involved [3]. Roberts
et al. reported the result of 113 necropsy patients with cardiac
sarcoidosis. They found that the left ventricular free wall is the
most common location for granulomas and scars (96%), followed
by the intra-ventricular septum (73%). Cardiac infiltration by
sarcoid granulomas in these locations may cause diminished
systolic contractile function or diastolic dysfunction more fre-
quently.
The diagnosis of cardiac involvement through MRI was limited
due to the retrospective nature of this study. This was possibly the
absence of a complete stack of short axis images to calculate LV
volumes and function and the relative high slice thickness (15 mm)
of STIR and EGE images, with consequent low spatial resolution,
compared to the current gold standard (6–10 mm, as used for
LGE).
Furthermore, recent research pointed out the importance of
biomarkers for the prognosis of patients with cardiac involvement
of sarcoidosis. Therefore the inclusion of e.g. plasma NT-proBNP
[36], high-sensitive cardiac troponin T [37], and NT-proatrial
natriuretic peptide [38] in future prospective studies may improve
the results.
Conclusion
In conclusion, cardiopulmonary exercise test (CPET) potentially
improves detection of cardiac sarcoidosis and should be imple-
mented in the routine evaluation of patients with histologically
proven sarcoidosis. Low OUES (,70%pred.), was the single best
predictor of cardiac sarcoidosis in our study. Therefore, OUES
should be assessed at each examination, also in submaximal tests.
Future studies need to confirm OUES as a clinically useful and
powerful predictor of cardiac sarcoidosis. In addition, the role of
OUES in monitoring of drug-treatment effects in patients with
cardiac sarcoidosis will be subject to further investigations.
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Table 5. Results of the multivariable analyses (stepwise forward pin,0.05; pout.0.1).
Variable Values b-coefficient 95% Confidence interval p-value
Continuous Values
OUES % predicted 0.942 0.886–1.01 0.056
LVEF continuous 0.751 0.591–0.944 0.014
radiographic stage Stage 0–4 Excluded from the model - 0.234
FEV1 continuous Excluded from the model - 0.326
VO2max continuous Excluded from the model - 0.069
DLCO/VA % predicted Excluded from the model - 0.206
Categorical Values
OUES categorical 100.434 1.992–5064 0.021
(cut-off 70% pred)
LVEF continuous 0.776 0.578–1.042 0.092
radiographic stage Stage 0–4 Excluded from the model - 0.215
FEV1 continuous Excluded from the model - 0.911
VO2max continuous Excluded from the model - 0.871
DLCO/VA % predicted Excluded from the model - 0.807
Two models were calculated with either OUES in continuous (upper table) or as categorical values (70% predicted, lower table).
doi:10.1371/journal.pone.0102333.t005
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